ArticleThe journal of prevention of Alzheimer's disease2026
Hazan J; Liu KY; Howard R. Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers. # TJPAD-D-26-00165.
Lutz FroelichPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.